Next Science unveils promising study results

Next Science (ASX:NXS) has announced the publication of a study highlighting the effectiveness of their product, XPERIENCETM, in preventing infections post-surgery. The study, led by Dr. Ravi Bashyal, analyzed 1,295 patients undergoing knee and hip arthroplasties, showing a zero percent infection rate with XPERIENCETM.

Key takeaways and future outlook

Next Science (ASX:NXS) has published a peer-reviewed study in the Journal of Orthopaedic Experience & Innovation, showcasing the potential of XPERIENCETM to prevent infections in knee and hip surgeries. The study reported a zero percent infection rate for patients using XPERIENCETM compared to a 0.5% rate in the control group. Next Science continues its dedication to advancing medical technology through its proprietary XBIO TM technology. With research and development efforts ongoing, the company aims to strengthen its position in the medical technology market and enhance patient outcomes.

Executive insights on the study's impact

This study adds to the growing clinical evidence supporting the use of XPERIENCETM as a key tool in reducing surgical site infections. We are committed to further research and collaboration with surgeons to demonstrate our product's effectiveness.